Literature DB >> 9141216

Potent immunogenic short linear peptide constructs composed of B cell epitopes and Pan DR T helper epitopes (PADRE) for antibody responses in vivo.

M F del Guercio1, J Alexander, R T Kubo, T Arrhenius, A Maewal, E Appella, S L Hoffman, T Jones, D Valmori, K Sakaguchi, H M Grey, A Sette.   

Abstract

Induction of humoral immune responses against protein antigen requires that two independent signals be delivered to B cells. It is currently assumed that simple monovalent synthetic peptides would not be effective immunogens for antibody responses because they would not be anticipated to effectively generate the necessary signals unless conjugated to a complex carrier system. In this study, the immunogenicity of short linear peptide constructs comprising Plasmodium vivax B cell epitopes (PVB) and non-natural Pan-DR T helper cell epitopes (PADRE) was assessed in mice and compared to other types of antigen constructs. The 33-residue PADRE-PVB linear constructs were highly immunogenic and induced responses comparable to those obtained with the multiple antigen peptides (MAP) constructs, both in terms of absolute titers and quality of antibody responses. The anti-PVB antibody responses were of long duration, composed mostly of IgG and reactive with intact sporozoites. The PADRE-PVB constructs were immunogenic when formulated in adjuvants such as Alum and Montanide ISA 51 underlining the relevance of these findings for vaccine development.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9141216     DOI: 10.1016/s0264-410x(97)00186-2

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  34 in total

Review 1.  The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination?

Authors:  Craig L Slingluff
Journal:  Cancer J       Date:  2011 Sep-Oct       Impact factor: 3.360

2.  Development of Autologous C5 Vaccine Nanoparticles to Reduce Intravascular Hemolysis in Vivo.

Authors:  Lingjun Zhang; Wen Qiu; Stephen Crooke; Yan Li; Areeba Abid; Bin Xu; M G Finn; Feng Lin
Journal:  ACS Chem Biol       Date:  2017-01-12       Impact factor: 5.100

Review 3.  Abeta DNA vaccination for Alzheimer's disease: focus on disease prevention.

Authors:  David H Cribbs
Journal:  CNS Neurol Disord Drug Targets       Date:  2010-04       Impact factor: 4.388

4.  Immunogenic Display of Purified Chemically Cross-Linked HIV-1 Spikes.

Authors:  Daniel P Leaman; Jeong Hyun Lee; Andrew B Ward; Michael B Zwick
Journal:  J Virol       Date:  2015-04-15       Impact factor: 5.103

5.  Synthesis of a trimeric gp120 epitope mimic conjugated to a T-helper peptide to improve antigenicity.

Authors:  Joan G Schellinger; Lieza M Danan-Leon; Jessica A Hoch; Aemro Kassa; Indresh Srivastava; David Davis; Jacquelyn Gervay-Hague
Journal:  J Am Chem Soc       Date:  2011-02-22       Impact factor: 15.419

6.  DNA and modified vaccinia virus Ankara vaccines encoding multiple cytotoxic and helper T-lymphocyte epitopes of human immunodeficiency virus type 1 (HIV-1) are safe but weakly immunogenic in HIV-1-uninfected, vaccinia virus-naive adults.

Authors:  Geoffrey J Gorse; Mark J Newman; Allan deCamp; Christine Mhorag Hay; Stephen C De Rosa; Elizabeth Noonan; Brian D Livingston; Jonathan D Fuchs; Spyros A Kalams; Farah L Cassis-Ghavami
Journal:  Clin Vaccine Immunol       Date:  2012-03-07

7.  A phase 1, randomized, controlled dose-escalation study of EP-1300 polyepitope DNA vaccine against Plasmodium falciparum malaria administered via electroporation.

Authors:  Paul Spearman; Mark Mulligan; Evan J Anderson; Andi L Shane; Kathy Stephens; Theda Gibson; Brooke Hartwell; Drew Hannaman; Nora L Watson; Karnail Singh
Journal:  Vaccine       Date:  2016-09-30       Impact factor: 3.641

Review 8.  Rationale for peptide and DNA based epitope vaccines for Alzheimer's disease immunotherapy.

Authors:  Anahit Ghochikyan
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-04       Impact factor: 4.388

Review 9.  The optimization of helper T lymphocyte (HTL) function in vaccine development.

Authors:  J Alexander; J Fikes; S Hoffman; E Franke; J Sacci; E Appella; F V Chisari; L G Guidotti; R W Chesnut; B Livingston; A Sette
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

Review 10.  Targeting antitumor CD4 helper T cells with universal tumor-reactive helper peptides derived from telomerase for cancer vaccine.

Authors:  Olivier Adotévi; Magalie Dosset; Jeanne Galaine; Laurent Beziaud; Yann Godet; Christophe Borg
Journal:  Hum Vaccin Immunother       Date:  2013-01-28       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.